SCHEMBL20489593

SCHEMBL20489593

CCOC(=O)c1cnc(Cl)cc1OCC

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.48
MAPT P10636 3/20 0.46
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
NPC1 O15118 1/20 0.44
MEN1 O00255 1/20 0.44
TSHR P16473 2/20 0.44
CYP3A4 P08684 1/20 0.44
HSP90AA1 P07900 1/20 0.43
CYP1A2 P05177 2/20 0.43
GLA P06280 1/20 0.43
GAA P10253 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20330955 0.89 DPP4 (0.54) DPP4MAPTKMT2AMEN1GAA
SCHEMBL16187216 0.86 GAA (0.46) DPP4MAPTKMT2AKDM4EALDH1A1
SCHEMBL7866700 0.85 TSHR (0.51) MAPTKMT2AKDM4EALDH1A1NPC1
SCHEMBL3516119 0.85 BAZ2B (0.49) DPP4MAPTKMT2AKDM4EALDH1A1
SCHEMBL24341945 0.84 CYP2C9 (0.50) DPP4MAPTKMT2AKDM4EALDH1A1
SCHEMBL31208511 0.84 DPP4 (0.41) DPP4KMT2AKDM4EALDH1A1NPC1
SCHEMBL25232131 0.84 DPP4 (0.41) DPP4KMT2AKDM4EALDH1A1NPC1
SCHEMBL13982866 0.84 DGAT1 (0.49) DPP4KMT2AKDM4EALDH1A1NPC1
SCHEMBL190973 0.84 BAZ2B (0.51) DPP4MAPTKMT2AKDM4EALDH1A1
SCHEMBL29574609 0.84 BAZ2B (0.51) DPP4MAPTKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3372601-B1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORP (JP) 2022-09-21 EP disclosed
US-10793582-B2 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-10-06 US disclosed
US-10793582-B2 Bicyclic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2020-10-06 US disclosed
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-08-01 US disclosed
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-08-01 US disclosed
EP-3372601-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2018-09-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233438-A1 NOVEL BICYCLIC HETEROCYCLIC COMPOUND KAT2A, KAT7, KAT5 DPP4 1149/4885MAPT 2348/4885KMT2A 91/4885
US-10793582-B2 Bicyclic heterocyclic compound KAT2A, KAT7, KAT5 DPP4 1012/4885MAPT 2057/4885KMT2A 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.